4/22/2022 | SP | New Issue: GS Finance sells $8 million basket-linked notes tied to 45 stocks
|
2/28/2019 | SP | New Issue: JPMorgan prices $1 million 9% yield notes Exelixis stock
|
6/7/2018 | SP | New Issue: Credit Suisse sells $1 million 9% three-month step reverse convertibles on Exelixis
|
6/29/2017 | LMPP | Exelixis repays Deerfield convertibles due 2018, its ‘last major’ debt
|
3/30/2017 | BK | Exelixis repays full $80 million of Silicon Valley Bank term loan
|
8/24/2016 | CVLM | Exelixis calls $48.1 million 4.25% subordinated convertibles due 2019
|
8/22/2016 | PP | Market Commentary: Biotech names eyed after Medivation takeout news; BioMarin convertibles add with shares
|
8/22/2016 | CV | Market Commentary: Biotech names eyed after Medivation takeout news; BioMarin convertibles add with shares
|
8/22/2016 | CVLM | Exelixis to swap stock, cash for $71.3 million of 4.25% convertibles
|
8/9/2016 | CVLM | Exelixis to swap stock, cash for $168.1 million of 4.25% convertibles
|
7/1/2016 | PP | Market Commentary: Convertibles quiet ahead of holiday; Exelixis in line; Softbank/Alibaba mandatories better
|
7/1/2016 | CV | Market Commentary: Convertibles quiet ahead of holiday; Exelixis in line; Softbank/Alibaba mandatories better
|
7/1/2016 | CV | Market Commentary: Morning Commentary: Convertibles quiet ahead of holiday weekend; Exelixis trading in line
|
5/31/2016 | CV | Market Commentary: Health care in focus as sector lifts; Softbank mandatory exchangeable into Alibaba on tap
|
5/23/2016 | PP | Market Commentary: Convertibles mostly quiet; XenoPort surges on takeout news; Allegheny Technologies rises
|
5/23/2016 | CV | Market Commentary: Convertibles mostly quiet; XenoPort surges on takeout news; Allegheny Technologies rises
|
3/2/2016 | CV | Market Commentary: Morning Commentary: Convertible bond market quiet at open; SunEdison’s 5% convertible stands at 56
|
3/1/2016 | PP | Market Commentary: Convertibles better as March gets underway; Seacor up; Exelixis expands; SunEdison swamped
|
3/1/2016 | CV | Market Commentary: Convertibles better as March gets underway; Seacor up; Exelixis expands; SunEdison swamped
|
3/1/2016 | CV | Market Commentary: Morning Commentary: Exelixis expands on swap on marketing pact; Workday in line as shares pop
|
1/5/2016 | PP | Market Commentary: Convertibles action picks up; tone improves; Exelixis bonds expand initially, then fade
|
1/5/2016 | CV | Market Commentary: Convertibles action picks up; tone improves; Exelixis bonds expand initially, then fade
|
1/5/2016 | CV | Market Commentary: Morning Commentary: Convertibles action picks up somewhat as broader markets steady; Exelixis eyed
|
8/11/2015 | PP | Market Commentary: Convertibles weaken; SunEdison, Tesla Motors down; PTC Therapeutics pulls off solid debut
|
8/11/2015 | CV | Market Commentary: Convertibles weaken; SunEdison, Tesla Motors down; PTC Therapeutics pulls off solid debut
|
8/11/2015 | CV | Market Commentary: Morning Commentary: New PTC Therapeutics holds up against weaker shares; Exelixis shares slip
|
7/21/2015 | CV | Market Commentary: Energy convertibles weak; Helix Energy down 2.5 points; United Tech mandatories in line
|
7/21/2015 | CV | Market Commentary: Morning Commentary: Whiting Petroleum weakens; Energy XXI down; United Tech mandatories in line
|
7/20/2015 | PP | Market Commentary: Exelixis jumps outright, expands on hedge on positive trial data; Depomed better on hedge
|
7/20/2015 | CV | Market Commentary: Exelixis jumps outright, expands on hedge on positive trial data; Depomed better on hedge
|
7/20/2015 | CV | Market Commentary: Morning Commentary: Exelixis jumps outright, expands on hedge on positive data; U.S. Steel drops
|
7/1/2015 | PP | Exelixis places $100 million of three-year convertibles with Deerfield
|
3/9/2015 | PP | Exelixis exercises option to extend private sale notes with Deerfield
|
2/13/2015 | PP | Market Commentary: Newmont, Tesla remain weaker; Microchip adds on hedge; Exelixis up; Oclaro taps market
|
2/13/2015 | CV | Market Commentary: Newmont, Tesla remain weaker; Microchip adds on hedge; Exelixis up; Oclaro taps market
|
9/8/2014 | DD | Market Commentary: Quiksilver looks to recoup losses; Walter, Endeavour weaken as ratings cut; NII gains strength
|
9/8/2014 | PP | Market Commentary: Convertibles muted as week kicks off; HSBC’s CoCo deal ahead; Exelixis looks for floor
|
9/8/2014 | CV | Market Commentary: Convertibles muted as week kicks off; HSBC’s CoCo deal ahead; Exelixis looks for floor
|
9/3/2014 | CV | Market Commentary: Planned Depomed, Electronics For Imaging add in the gray; Huron Consulting notes on tap
|
9/3/2014 | CV | Market Commentary: Morning Commentary: New deals in focus; Clovis Oncology shares sharply lower; Exelixis slips
|
7/15/2014 | CV | Market Commentary: Morning Commentary: Citrix trading actively again; Macquarie adds; Blackstone trades at 108.5
|
7/14/2014 | PP | Market Commentary: Macquarie stretches to 107; Tesla flat to better on higher shares; Exelixis stock surges
|
7/14/2014 | CV | Market Commentary: Macquarie stretches to 107; Tesla flat to better on higher shares; Exelixis stock surges
|
3/26/2014 | CV | Market Commentary: New HomeAway trades up; Solazyme shares drop; Exelixis slumps outright, expands on hedge
|
1/27/2014 | CV | Market Commentary: Midday Commentary: Regis, Rayonier convertibles in focus as those shares make big swings
|
1/27/2014 | CV | Market Commentary: Regis trades lower outright, adds on hedge; Steel Dynamics in line on hedge; Ford in focus
|
1/22/2014 | PPPV | Exelixis gets option to extend private placement notes, issue more
|
1/7/2014 | CV | Market Commentary: Midday Commentary: Activity broadens out; volume still light; MGM, Exelixis gap higher
|
1/7/2014 | CV | Market Commentary: Tower Group jumps in active trade; MGM, Exelixis up outright, little changed on hedge
|
9/26/2013 | CV | Market Commentary: New Maiden mandatory holds at par against lower common stock; DryShips flat; Cemex in line
|
9/25/2013 | CV | Market Commentary: Maiden mandatory prices at the mids; deal eyed as cheap ahead of terms; Rallye prices
|
8/14/2012 | CV | Exelixis greenshoe exercised, lifts convertible sale to $287.5 million
|
8/10/2012 | CV | Market Commentary: MGM better on outright demand; Janus adds on investment stake; Hornbeck trades up, in line
|
8/9/2012 | CV | New Issue: Exelixis sells upsized $250 million seven-year convertibles to yield 4.25%, up 25%
|
8/9/2012 | CV | Market Commentary: New Exelixis gains on debut; new Prospect Capital prices at a discount; Medicis better
|
8/8/2012 | CV | Market Commentary: Isis pops on debut; older paper slips again; new Hornbeck adds; Tyson comes 'in' slightly
|
8/6/2012 | PV | Exelixis amends purchase agreement to allow issuance of convertibles
|
8/6/2012 | CV | Exelixis plans to price $225 million seven-year convertibles to yield 3.75%-4.25%, up 25%-30%
|
8/6/2012 | CV | Market Commentary: Knight extends strong gains on capital infusion; Isis moves up with shares, launches deal
|
6/8/2012 | CVHYPF | Exelixis files automatic shelf covering debt, stock and preferreds
|
6/3/2010 | PV | Exelixis to raise $160 million through pair of financing transactions
|
7/24/2009 | SS | Market Commentary: Bristol-Meyers predicted to continue deal pace; proxy firm sides with Foundation Coal buyout
|
4/24/2009 | CVHY | Exelixis files $250 million stock, debt securities shelf registration
|
11/10/2008 | SS | T. Rowe Price reports 10.5% passive stake in Exelixis
|
6/5/2008 | PP | New Issue: Exelixis arranges $150 million credit facility
|
6/5/2008 | PP | Market Commentary: Exelixis gets $150 million facility; Brockman sells stock; Genta offers convertible; Deep Down closes deal
|
11/2/2006 | BT | Market Commentary: Exelixis stock off 12% after XL999 trial suspended; ViroPharma reports $23.3 million Q3 net income
|
10/18/2006 | BT | Exelixis on track to file three NDAs and end year with $130 million
|
10/10/2006 | BT | Exelixis greenshoe exercised, raising follow-on stock sale to $96.6 million
|
10/5/2006 | BT | Market Commentary: AnorMED up 7% as Genzyme boosts bid; GenVec gains 18%; Acorda rises; Light Sciences at bat
|
10/5/2006 | BT | New Issue: Exelixis prices upsized $84 million shares at $8.40, discounted from $8.61 close
|
10/4/2006 | BT | Market Commentary: Acorda off on $31.5 million deal; Dynavax up 13%; Advancis up 8%; AVI falls 7%; Exelixis at bat
|
10/3/2006 | BT | Market Commentary: Acorda shoots up 32%; Isis lower after analyst day; Gilead off 3.5%, Myogen eases; Amgen better
|
10/2/2006 | BT | Market Commentary: Gilead off, Myogen skyrockets; Accentia up, Biovest off; GTC up after close; Encysive off 3%
|
9/29/2006 | BT | Market Commentary: Exelixis follow-on set for Oct. 2 week; ImaRx on tap; Biomira bounces; Labopharm, Pharmacopeia lower
|
9/27/2006 | BT | Exelixis launches follow-on offering of 9 million shares via Goldman Sachs
|
8/31/2006 | BT | Exelixis files IND for cancer drug candidate XL228
|
8/29/2006 | BT | Market Commentary: Teva lower; Endo, Penwest up; StemCells gains 7%; Nastech higher; Hemispherx rises 11%
|
8/1/2006 | BT | Exelixis begins phase 2 study of XL647 in non-small cell lung cancer
|
6/28/2006 | BT | Exelixis begins phase 2 program for XL880 in patients with papillary renal cell carcinoma
|
6/20/2006 | BT | Exelixis says it will report noteworthy amount of clinical data in next 12 months
|
6/6/2006 | BT | Exelixis says XL647 well-tolerated in phase 1 study for treatment of cancer
|
6/5/2006 | BT | Exelixis fails to meet primary objective in XL880 trial
|
5/25/2006 | BT | Exelixis to present data from phase 1 trials of XL647, XL880 and XL999 in cancer at oncology meeting
|
5/23/2006 | BT | Exelixis repays $30 million convertible promissory note
|
5/18/2006 | BT | Market Commentary: Neurocrine piles on more losses; DOV adds back 10%; Celgene sees buying on dip; Exelixis up
|
3/27/2006 | BT | Exelixis starts phase 2 program for XL784 in diabetes patients
|
3/20/2006 | BT | Exelixis, Sankyo sign $20 million deal to develop therapies for cardiovascular disease
|
2/22/2006 | BT | Exelixis maintained at market perform by Merrill
|
12/22/2005 | BT | Exelixis, Wyeth sign license agreement for metabolic disease compounds
|
12/20/2005 | BT | Exelixis begins phase 2 trials for cancer drug XL999
|
12/6/2005 | BT | Market Commentary: Cephalon dips on acquisition; New River off; Ipsen prices IPO in France; Exelixis ends off highs
|
12/6/2005 | BT | Exelixis, Bristol-Myers to collaborate on development of drugs for cardiovascular, metabolic disorders
|
11/17/2005 | BT | Exelixis' phase 1 trial of XL999 sets dosing levels, shows evidence of action against tumors
|
8/17/2005 | BT | New Issue: Exelixis raises $50.375 million in follow-on at $7.75, discounted from $8.20 close
|
8/17/2005 | BT | Market Commentary: Access in talks to dodge a forced bankruptcy; Exelixis trades down to follow-on level; Insmed seesaws
|
7/19/2005 | BT | Exelixis initiated by Global Crown at underweight
|
10/27/2004 | CVHY | Exelixis files $200 million shelf
|